The roles of PD-L1 as an inducer of tumor cell properties that elevate tumor progression suggest that therapeutic strategies directed towards its immune-suppressive properties, alongside with measures inhibiting its cell-autonomous functions, should be considered in breast cancer therapy. Here, CD274 is linked to breast cancer.